<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566566</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-07-4861-YW-CTIL</org_study_id>
    <nct_id>NCT00566566</nct_id>
  </id_info>
  <brief_title>Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors</brief_title>
  <official_title>Adipocytokines as Predictors of the Metabolic Syndrome in Survivors of Childhood Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It
      accounts for 25% of all childhood cancers. Peak incidence occurs between 2 to 5 years of age.
      Modern treatment regimens have improved cure rates from virtually zero (in the 1950's) to
      current overall survival rates of approximately 80%.The high survival rates have introduced
      us to novel medical problems as a consequences of the different treatment regimens. No single
      treatment modality exists today but rather several treatment protocols are accepted
      worldwide. As such, the population of the childhood ALL survivors differ in their toxic
      exposure: cranial &amp; spinal radiotherapy, intrathecal and/or systemic chemotherapy and bone
      marrow transplantation .As the survival rates grow, there are more young adult ALL survivors
      worldwide susceptible to these late effects of treatment.

      Numerous reports have pointed out that this particular group is at increased risk to develop
      cardiovascular disease (CVD) and diabetes (MS). The metabolic syndrome, i.e hypertension,
      dyslipidemia, impaired glucose metabolism and obesity, occurs at a younger age than the
      general population.

      Adipocytokines, mediators secreted by adipose tissue, play an important role in the
      regulation of carbohydrates and lipid metabolism.Changes in serum adipokine levels precede
      the clinical symptoms.

      We aim to identify and assess prevalence of the MS in ALL survivors. We aim to characterize
      the population at risk to develop DM and CVD prior to overt clinical disease.
      Characterization will be done by measuring serum adipocytokines and inflammatory cytokine
      profiles .Biochemical characterization of the group at risk will enable us to intervene in
      the preventive stage in the future.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Leukemia</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>ALL survivors 5 years after completion of treatment, during routine medical follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sample without DNA</intervention_name>
    <description>family history, anthropometric measurements and blood sampling</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum leptin, resistin ,adiponectin ,CRP, PAI ,TNF-Î±, IL-6 will be taken as part of initial
      blood test screening in patients following an overnight fast. Adiponectin and leptin levels
      will be determined by RIA (Linco, St. Charles, MO), Insulin, will be determined by
      chemiluminescent immunometric method (Immulite 2000, Diagnostic Products Corporation, Los
      Angeles, CA).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hematoncological pediatric clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALL diagnosis

          -  five years after completion of treatment

          -  leukemia free during research

        Exclusion Criteria:

          -  ongoing chemotherapy and radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael Weintraub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bella Bielorai, MD</last_name>
    <phone>972-3-5302692</phone>
    <email>Bella.Bielorai@sheba.health.gov.il</email>
  </overall_contact>
  <reference>
    <citation>Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005 Apr 16-22;365(9468):1415-28. Review.</citation>
    <PMID>15836891</PMID>
  </reference>
  <reference>
    <citation>Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62.</citation>
    <PMID>16182882</PMID>
  </reference>
  <reference>
    <citation>Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003 Aug;157(8):821-7.</citation>
    <PMID>12912790</PMID>
  </reference>
  <reference>
    <citation>Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet. 2000 Sep 16;356(9234):993-7.</citation>
    <PMID>11041401</PMID>
  </reference>
  <reference>
    <citation>Gurney JG, Ness KK, Sibley SD, O'Leary M, Dengel DR, Lee JM, Youngren NM, Glasser SP, Baker KS. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer. 2006 Sep 15;107(6):1303-12.</citation>
    <PMID>16894525</PMID>
  </reference>
  <reference>
    <citation>Mohn A, Di Marzio A, Capanna R, Fioritoni G, Chiarelli F. Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia. Lancet. 2004 Jan 10;363(9403):127-8.</citation>
    <PMID>14726167</PMID>
  </reference>
  <reference>
    <citation>Razzouk BI, Rose SR, Hongeng S, Wallace D, Smeltzer MP, Zacher M, Pui CH, Hudson MM. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2007 Apr 1;25(10):1183-9.</citation>
    <PMID>17401007</PMID>
  </reference>
  <reference>
    <citation>Kourti M, Tragiannidis A, Makedou A, Papageorgiou T, Rousso I, Athanassiadou F. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol. 2005 Sep;27(9):499-501.</citation>
    <PMID>16189445</PMID>
  </reference>
  <reference>
    <citation>Oeffinger KC, Buchanan GR, Eshelman DA, Denke MA, Andrews TC, Germak JA, Tomlinson GE, Snell LE, Foster BM. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30.</citation>
    <PMID>11878576</PMID>
  </reference>
  <reference>
    <citation>Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):525-46. Review.</citation>
    <PMID>16311215</PMID>
  </reference>
  <reference>
    <citation>Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, Sandlund JT, Ribeiro RC, Relling MV, Kun LE, Evans WE, Hudson MM. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003 Aug 14;349(7):640-9. Erratum in: N Engl J Med. 2003 Sep 25;349(13):1299.</citation>
    <PMID>12917300</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <last_update_submitted>November 30, 2007</last_update_submitted>
  <last_update_submitted_qc>November 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2007</last_update_posted>
  <responsible_party>
    <name_title>Dr. Yael Weintraub</name_title>
    <organization>Sheba Medical Cener</organization>
  </responsible_party>
  <keyword>adipocytokines</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>Leptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

